Eugenia Ruiz
Chief Scientific Officer GAT Therapeutics
Eugènia Ruiz Cánovas is the CSO of GAT Therapeutics (GATTx) and leads the development of GTX-11 for pulmonary fibrosis. She holds a PhD in Biotechnology from the University of Barcelona and has a background in molecular biology, protein engineering, and drug development. Her research on therapeutic compounds led to the foundation of GATTx, where she has guided GTX-11 from early discovery to phase I clinical trials. With nine patent applications and multiple international presentations, she plays a key role in advancing innovative treatments for fibrotic diseases.
Seminars
Thursday 21st August 2025
Exploring a Novel TGF-β Pathway Modulator
4:30 pm
- GTX-11, an orally available TGF-β pathway modulator, has shown potent anti-fibrotic, anti-inflammatory, and vascular-protective effects across multiple preclinical models, including bleomycin-induced lung fibrosis, patient-derived fibroblasts, and precision-cut lung slices (PCLS)
- With an excellent preclinical safety and toxicology profile, GTX-11 effectively reduces SMAD2/3 activation, fibroblast-to-myofibroblast transition, and vascular dysfunction, positioning it as a promising therapeutic candidate
- Now in Phase I clinical trials, GTX-11 represents a promising new approach for treating fibrotic interstitial lung diseases (ILDs), offering potential advantages over existing therapies
